Walgreens changes in-store clinic strategy with closures, partnerships

Walgreens is switching up its approach to in-store clinics, closing the clinics it operates and keeping those run by other health systems.

The news was announced during the company’s recent quarterly earnings call with investors this week and was covered by The Wall Street Journal. Walgreens owns and operates approximately 160 walk-in clinics and will keep another 217 that are operated by local healthcare providers. Co-chief operating officer Alex Gourlay called the Walgreens-owned clinics “loss making.” The company––as well as its competitor CVS Health, which operates 1,000 in-store clinics––has “at best” broken even operating in-store clinics, the WSJ reported.

The strategic change is part of an effort from Walgreens Boots Alliance to cut costs and outsource medical services in stores. In fact, the company wants to cut more than $1.8 billion in annual costs by 2022.

Walgreens is transitioning seven of its in-store clinics in Cincinnati to TriHealth, a not-for-profit health system with six hospitals and 130 sites of care, the company announced Oct. 28. It is also adding Jenny Craig as a partner to bring health and weight loss management services to 100 locations nationwide in January 2020.

While it plans to close its in-store clinics, Walgreens plans to open smaller stores in big cities to keep costs down. For the financial quarter closing out 2019, Walgreens reported a profit of $677 million, compared to $1.51 billion last year. The company will close the financial year “roughly flat year-on-year,” according to CEO and executive vice chairman Stefano Pessina.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.